1. Subjective cognitive decline and stage 2 of Alzheimer disease in patients from memory centers.
- Author
-
Jessen, Frank, Wolfsgruber, Steffen, Kleineindam, Luca, Spottke, Annika, Altenstein, Slawek, Bartels, Claudia, Berger, Moritz, Brosseron, Frederic, Daamen, Marcel, Dichgans, Martin, Dobisch, Laura, Ewers, Michael, Fenski, Friederike, Fliessbach, Klaus, Freiesleben, Silka D., Glanz, Wenzel, Görß, Doreen, Gürsel, Selim, Janowitz, Daniel, and Kilimann, Ingo
- Abstract
Introduction: It is uncertain whether subjective cognitive decline (SCD) in individuals who seek medical help serves the identification of the initial symptomatic stage 2 of the Alzheimer's disease (AD) continuum. Methods: Cross‐sectional and longitudinal data from the multicenter, memory clinic–based DELCODE study. Results: The SCD group showed slightly worse cognition as well as more subtle functional and behavioral symptoms than the control group (CO). SCD–A+ cases (39.3% of all SCD) showed greater hippocampal atrophy, lower cognitive and functional performance, and more behavioral symptoms than CO–A+. Amyloid concentration in the CSF had a greater effect on longitudinal cognitive decline in SCD than in the CO group. Discussion: Our data suggests that SCD serves the identification of stage 2 of the AD continuum and that stage 2, operationalized as SCD‐A+, is associated with subtle, but extended impact of AD pathology in terms of neurodegeneration, symptoms and clinical progression. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF